Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
193.47
-0.15 (-0.08%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AbbVie
< Previous
1
2
3
4
5
6
7
Next >
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
September 19, 2023
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Economy
Product Safety
High Yield, Low Beta Stocks to Buy for the Next Market Meltdown
September 12, 2023
The market is set up for a fall, and it may start soon, as soon as the CPI data is released. These low-beta stocks are poised to outperform and pay dividends
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
Interest Rates
US Equities
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
July 14, 2023
Via
Investor Brand Network
AbbVie Inc. (NYSE: ABBV) Making Surprising Moves in Monday Session
April 24, 2023
Via
Investor Brand Network
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
September 07, 2023
Data readout expected in Q4 2024
From
Alector, Inc.
Via
GlobeNewswire
A Significant Reversal is in Sight for These 5 Med Tech Companies
August 30, 2023
Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand.
Via
MarketBeat
5 Best Stocks to Buy in a Bear Market
August 11, 2023
Want income-producing assets and stable stocks? Look for stocks with stable cash flow in rock-solid industries for the best stocks to buy in a bear market.
Via
MarketBeat
Topics
Economy
Exposures
Economy
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
August 11, 2023
Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains
Via
MarketBeat
Exposures
COVID-19
Is Growth Priced into Amgen Stock after Earnings Beat?
August 07, 2023
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock.
Via
MarketBeat
The Patent Cliff Is Why AbbVie Is Moving Higher
July 28, 2023
High-yielding AbbVie will retest the all-time high after posting a solid quarter underpinned by new treatments and relative strength in Humira.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
3 Dividend Stocks That Still Make Sense in 2023
July 17, 2023
Investors are still faced with an uncertain market which is favorable for these three dividend stocks regardless of what happens in the economy
Via
MarketBeat
Topics
Economy
Exposures
Economy
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
May 02, 2023
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase
April 26, 2023
From
Hagens Berman Sobol Shapiro LLP
Via
Business Wire
Why Next Week's Earnings Report is Good for Johnson & Johnson
April 13, 2023
Investors have had to digest some negative news headlines, but if you look past that a dividend king like JNJ can be a boring but reliable buy in this market
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
BioNTech Is Ripe For A Rebound In 2023
March 27, 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
These 3 Dividend Growers Yield More Than the 10-Year Note
March 22, 2023
Dividend aristocrats with yields greater than the 10-year note yield plus the potential for price appreciation could be a winning formula in this environment.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Healthcare Stocks With at Least 30 Years of Dividend Increases
March 14, 2023
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.
Via
MarketBeat
Diversify Your Income with These 2 High-Yielding Dividend ETFs
March 14, 2023
Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and indust
Via
MarketBeat
Topics
ETFs
How to Pick the Best Dividend Stocks
March 07, 2023
A stock’s dividend yield is a key metric for investors, so what is a good dividend yield? We’ll explore the answer in this article.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
The Stock That Tripled in a Day...And May Not Be Done
March 07, 2023
Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios?
Via
MarketBeat
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
March 02, 2023
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify.
Via
MarketBeat
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
February 22, 2023
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.
Via
MarketBeat
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Via
MarketBeat
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
MarketBeat Week in Review – 2/13 - 2/17
February 18, 2023
Retail sales were up but so was inflation which meant more volatility for stocks. Enjoy your holiday weekend and catch up on our most read stories this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
February 17, 2023
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors.
Via
MarketBeat
AbbVie Has a Mixed Outlook After Mixed Earnings
February 13, 2023
AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold
Via
MarketBeat
Topics
Earnings
Intellectual Property
Exposures
Financial
Intellectual Property
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
January 25, 2023
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
Via
MarketBeat
AbbVie Stock: Dividend King ABBV Overview
January 19, 2023
Via
MarketBeat
4 High-Yield Dividend Kings For 2023
January 16, 2023
These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.